Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cogent Biosciences, Inc.COGT · Entity 3793 | Chief Commercial Officer | December 17, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cogent Biosciences, Inc.
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,450 |
Reported balance
After 2025-12-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-17 · Grant · Acquired 50,000 · Balance 97,450 F1: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates. F2: Includes an aggregate of 1,602 shares of common stock acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on June 30, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 311,450 |
Reported balance
After 2025-12-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-12-17 · Grant · Acquired 214,000 · Balance 311,450 F3: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 216,650 |
Reported balance
After 2025-12-17 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-12-17 · Tax withholding · Disposed 94,800 · Balance 216,650 F4: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs. F5: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2035-12-17 | Direct | 65,000 |
Reported balance
After 2025-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-17 · Grant · Acquired 65,000 · Balance 65,000 F6: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
F2: Includes an aggregate of 1,602 shares of common stock acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on June 30, 2025.
F3: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").
F4: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
F5: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F6: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $39.45 | $0.00 |
DisclosureSEC source: 0001193125-25-326774 · ownership.xml · derivative · entry 4 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-12-17 F6 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | Tax withholdingCommon Stock | 94,800 | $39.45 | $3,739,860.00 |
DisclosureSEC source: 0001193125-25-326774 · ownership.xml · nonDerivative · entry 3 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,650 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 214,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326774 · ownership.xml · nonDerivative · entry 2 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,450 F3 · shares: Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs"). Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 16:01 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-326774 · ownership.xml · nonDerivative · entry 1 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,450 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates. F2 · balance_after: Includes an aggregate of 1,602 shares of common stock acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 17:00 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0000950170-25-009266 · ownership.xml · derivative · entry 1 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: This stock option shall vest in equal monthly installments over a four year period. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 07:00 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | PurchaseCommon Stock | 43,750 | $7.60 | $332,412.50 |
DisclosureSEC source: 0000950170-25-005630 · ownership.xml · nonDerivative · entry 1 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,848 F1 · price: The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $7.53 to $7.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes an aggregate of 1,398 shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| May 25, 2024 Filed May 29, 2024 16:03 UTC | Cogent Biosciences, Inc. COGT · Entity 3793 | GrantStock Option (Right to Buy) · Derivative | 525,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000950170-24-065900 · ownership.xml · derivative · entry 1 Pinnow Cole · CIK 0002024135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2034-05-25 F1 · derivative.exercise_date: This stock option shall vest 25% on the first anniversary of May 25, 2024, with the remainder vesting in equal monthly installments through May 25, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.